Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2026)

Arcturus Therapeutics Holdings has reported Cash & Equivalents for 9 years, with the latest figure at $211.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 2.57% year-over-year to $211.4 million; the trailing twelve-month figure through Mar 2026 stood at $211.4 million (down 2.57% YoY), and the FY2025 full-year result was $230.9 million, down 21.44% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $211.4 million, down from $230.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $391.9 million in Q4 2022, with the low at $180.4 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $270.8 million across 5 years, with a median of $283.5 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 42.57% — and 2023, when it surged 31.24%.
• Arcturus Therapeutics Holdings' Cash & Equivalents stood at $391.9 million in 2022, then declined by 25.49% to $292.0 million in 2023, then gained by 0.65% to $293.9 million in 2024, then fell by 21.44% to $230.9 million in 2025, then declined by 8.46% to $211.4 million in 2026.
• The last three Cash & Equivalents figures came in at $211.4 million (Q1 2026), $230.9 million (Q4 2025), and $180.4 million (Q3 2025), per Business Quant data.